JP2002515868A5 - - Google Patents

Download PDF

Info

Publication number
JP2002515868A5
JP2002515868A5 JP1997533690A JP53369097A JP2002515868A5 JP 2002515868 A5 JP2002515868 A5 JP 2002515868A5 JP 1997533690 A JP1997533690 A JP 1997533690A JP 53369097 A JP53369097 A JP 53369097A JP 2002515868 A5 JP2002515868 A5 JP 2002515868A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997533690A
Other languages
English (en)
Japanese (ja)
Other versions
JP4210734B2 (ja
JP2002515868A (ja
Filing date
Publication date
Priority claimed from US08/821,739 external-priority patent/US20020168374A1/en
Application filed filed Critical
Publication of JP2002515868A publication Critical patent/JP2002515868A/ja
Publication of JP2002515868A5 publication Critical patent/JP2002515868A5/ja
Application granted granted Critical
Publication of JP4210734B2 publication Critical patent/JP4210734B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP53369097A 1996-03-21 1997-03-21 Hla結合ペプチド及びその使用 Expired - Lifetime JP4210734B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1383396P 1996-03-21 1996-03-21
US08/821,739 US20020168374A1 (en) 1992-08-07 1997-03-20 Hla binding peptides and their uses
US08/821,739 1997-03-20
US60/013,833 1997-03-20
PCT/US1997/004451 WO1997034617A1 (en) 1996-03-21 1997-03-21 Hla binding peptides and their uses

Publications (3)

Publication Number Publication Date
JP2002515868A JP2002515868A (ja) 2002-05-28
JP2002515868A5 true JP2002515868A5 (enExample) 2004-12-02
JP4210734B2 JP4210734B2 (ja) 2009-01-21

Family

ID=26685309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53369097A Expired - Lifetime JP4210734B2 (ja) 1996-03-21 1997-03-21 Hla結合ペプチド及びその使用

Country Status (8)

Country Link
US (1) US20020168374A1 (enExample)
EP (1) EP0888120B1 (enExample)
JP (1) JP4210734B2 (enExample)
CN (1) CN1218404A (enExample)
AU (1) AU725550B2 (enExample)
BR (1) BR9708217A (enExample)
CA (1) CA2248659A1 (enExample)
WO (1) WO1997034617A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US6265215B1 (en) * 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
WO1999003972A1 (en) * 1997-07-15 1999-01-28 Takara Shuzo Co., Ltd. Cytotoxic t lymphocytes
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
JP2002507397A (ja) * 1998-03-13 2002-03-12 エピミューン,インコーポレイティド Hla結合ペプチド及びその使用
EP1078092B1 (en) * 1998-05-13 2011-08-03 Epimmune Inc. Expression vectors for stimulating an immune response and methods of using the same
KR20010071848A (ko) * 1998-07-10 2001-07-31 교고 이또 Sart-1 유래의 종양 항원 펩티드
US20070020327A1 (en) * 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US6395714B1 (en) * 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
JP2003509465A (ja) * 1999-07-19 2003-03-11 エピミューン, インコーポレイテッド ペプチドおよび核酸組成物を使用する、c型肝炎ウイルスに対する細胞性免疫応答の誘導
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
CA2386341A1 (en) 1999-11-18 2001-05-25 Epimmune Inc. Heteroclitic analogs and related methods
EP1235848A4 (en) * 1999-12-10 2005-02-09 Epimmune Inc INDUCING CELLULAR IMMUNE RESPONSES TO CARCINOEMBRYONIC ANTIGEN USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
EP1237564A4 (en) * 1999-12-10 2005-05-04 Epimmune Inc TRIGGERING OF CELLULAR IMMUNE RESPONSES AGAINST P53 USING NUCLEIC ACID AND PEPTIDE COMPOSITIONS
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
AU2605501A (en) * 1999-12-21 2001-07-03 Epimmune, Inc. Inducing cellular immune responses to prostate cancer antigens using peptide andnucleic acid compositions
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
JP2004508340A (ja) * 2000-09-01 2004-03-18 エピミューン インコーポレーティッド Hla結合ペプチドおよびその使用方法
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US20040202654A1 (en) 2001-04-09 2004-10-14 Mayo Foundation For Medical Education & Research Methods and materials for cancer treatment
WO2005012502A2 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
WO2005118626A2 (en) * 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
JP4475469B2 (ja) * 2005-01-25 2010-06-09 日本電気株式会社 Hla結合性ペプチド、それをコードするdna断片および組み換えベクター
EP1851247A2 (en) 2005-02-15 2007-11-07 Thymon L.L.C. Methods and compositions for impairing multiplication of hiv-1
CN105566450A (zh) * 2007-07-27 2016-05-11 伊玛提克斯生物技术有限公司 免疫疗法的新型免疫抗原表位
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
JP2010001303A (ja) * 2009-08-17 2010-01-07 Pharmexa Inc Hla結合ペプチド及びその使用
EP2745845A1 (en) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
CN120712104A (zh) * 2022-10-14 2025-09-26 广东天科雅生物医药科技有限公司 针对神经胶质瘤的肽疫苗及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2143335C (en) * 1992-08-31 2000-03-14 Thierry Boon-Falleur Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
JP3814828B2 (ja) * 1993-10-19 2006-08-30 味の素株式会社 Hivに対する免疫応答を誘導できるペプチド及び該ペプチドを含む抗aids予防・治療剤
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2001507604A5 (enExample)
JP2000501771A5 (enExample)
JP2001506095A5 (enExample)
JP2000501599A5 (enExample)
JP2001502570A5 (enExample)
JP2001508674A5 (enExample)
JP2001511883A5 (enExample)
JP2000502472A5 (enExample)
JP2000501825A5 (enExample)
JP2000511355A5 (enExample)
JP2000516851A5 (enExample)
JP2000508995A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000516698A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2001504331A5 (enExample)
JP2002515868A5 (enExample)
JP2000501744A5 (enExample)
JP2001504813A5 (enExample)
JP2000502316A5 (enExample)